JPS63147473A - Composite type body fluids treatment apparatus - Google Patents
Composite type body fluids treatment apparatusInfo
- Publication number
- JPS63147473A JPS63147473A JP29469086A JP29469086A JPS63147473A JP S63147473 A JPS63147473 A JP S63147473A JP 29469086 A JP29469086 A JP 29469086A JP 29469086 A JP29469086 A JP 29469086A JP S63147473 A JPS63147473 A JP S63147473A
- Authority
- JP
- Japan
- Prior art keywords
- separation device
- plasma
- membrane
- body fluid
- hollow fiber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001124 body fluid Anatomy 0.000 title claims description 26
- 239000010839 body fluid Substances 0.000 title claims description 26
- 238000011282 treatment Methods 0.000 title claims description 17
- 239000002131 composite material Substances 0.000 title claims description 12
- 238000000926 separation method Methods 0.000 claims description 58
- 239000012528 membrane Substances 0.000 claims description 55
- 239000012510 hollow fiber Substances 0.000 claims description 41
- 239000011148 porous material Substances 0.000 claims description 17
- 238000005194 fractionation Methods 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 2
- 238000004064 recycling Methods 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 description 52
- 210000004369 blood Anatomy 0.000 description 26
- 239000008280 blood Substances 0.000 description 26
- 239000000126 substance Substances 0.000 description 16
- 239000013076 target substance Substances 0.000 description 16
- 239000000306 component Substances 0.000 description 15
- 102000009027 Albumins Human genes 0.000 description 9
- 108010088751 Albumins Proteins 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 238000000034 method Methods 0.000 description 6
- 210000000601 blood cell Anatomy 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 230000004087 circulation Effects 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 229920001747 Cellulose diacetate Polymers 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 239000012503 blood component Substances 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010018873 Haemoconcentration Diseases 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 206010048628 rheumatoid vasculitis Diseases 0.000 description 1
Abstract
(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】
（産業上の利用分野）
本発明は、全血、血漿、リンパ液等の体液から不要もし
くは有害である特定分子量領域の蛋白質等の物質を除去
、或は該体液から成分輸血などで多量に使用される特定
分子量領域の蛋白質等（例えばアルブミン）を採取する
為の体液処理装置に関する。Detailed Description of the Invention (Industrial Application Field) The present invention is a method for removing unnecessary or harmful substances such as proteins in a specific molecular weight range from body fluids such as whole blood, plasma, and lymph, or for removing components from body fluids. The present invention relates to a body fluid processing device for collecting proteins in a specific molecular weight range (for example, albumin) that are used in large quantities in blood transfusions and the like.
（従来技術とその問題点）
近年、体外循環により血液等の体液中の病因物質或は異
常蛋白などを除去する治療法の発展はめざましいものが
ある。例えば、人工腎臓を使用した血液透析療法、血液
を血球と血漿に分離する血漿分離器を使用した血漿交換
療法、更には血漿分離器及び血漿成分分離器を使用した
二重濾過血漿交換療法などがあげられる。血漿成分分離
器とは、あらかじめ血液から分離された血漿を、更に大
分子量物質と小分子量物質に分離するものである。こ打
ら体液の体外循環による治療のうち、特に血漿交換療法
及び二重濾過血漿交換療法は、従来よりこれといった有
効な治療法がなかフた難病、例えば、悪性関節リウマチ
、多発性骨髄腫、マクログロブリン血症、ギランバレー
症候群、劇症肝炎などに適用され、その効果が注目され
ている。(Prior art and its problems) In recent years, there has been remarkable progress in therapeutic methods for removing pathogenic substances or abnormal proteins from body fluids such as blood through extracorporeal circulation. Examples include hemodialysis therapy using an artificial kidney, plasma exchange therapy using a plasma separator that separates blood into blood cells and plasma, and double filtration plasma exchange therapy using a plasma separator and plasma component separator. can give. A plasma component separator is a device that further separates plasma, which has been previously separated from blood, into large molecular weight substances and small molecular weight substances. Among the treatments using extracorporeal circulation of body fluids, plasma exchange therapy and double filtration plasma exchange therapy are particularly useful for treating incurable diseases for which no effective treatment has been available until now, such as malignant rheumatoid arthritis, multiple myeloma, It has been used to treat macroglobulinemia, Guillain-Barre syndrome, fulminant hepatitis, etc., and its effects are attracting attention.
しかし、これらの療法中、とくに二重１！過血漿交換療
法は、血漿分離器と血漿成分分離器の二個の濾過器を使
用し、またそれらを結ぶ血液回路、圧力測定ライン、及
び血液を送り込むポンプ部など、複雑な接続を要し、更
に、ブライミング（回路、血液処理器内の洗浄及び生理
食塩水充填）に多大な時間を要すなど治療に先たつ準備
に手間がかかり手軽にどこでも実施できないという欠点
、及び接続間違いを起こす可能性が高いなどという問題
点がある。本出願人は先に、これらの問題点を解決する
ために、特開昭６１−１２２８７１号（特願昭５９−２
４２４８３号）の発明を提示した。しかしこの発明は、
血漿浄化室（血漿分画膜）の中空糸束の中に血球成分を
通す導管が存在するため、体外循環血液容量が増加し、
また製造に手間がかかること、また、血漿浄化室の血漿
成分分画中空糸膜は継手側が開口しておらず、ブライミ
ングにおいて洗浄しにくく、かつ十分に洗浄されないこ
と、中空糸内に気泡が残りやすく、体外循環終了後の返
血の際、該中空糸内に残っている浄化血漿が返血しにく
い等の欠点を有していた。However, during these treatments, especially double 1! Hyperplasma exchange therapy uses two filters, a plasma separator and a plasma component separator, and requires complex connections such as a blood circuit that connects them, a pressure measurement line, and a pump that pumps the blood. Furthermore, preparations prior to treatment are time consuming, such as briming (cleaning the circuit, blood processing device, and filling with physiological saline), which cannot be carried out easily anywhere, and there is a possibility of connection errors. There are problems such as high In order to solve these problems, the present applicant previously proposed Japanese Patent Application Laid-Open No. 122871/1983 (Japanese Patent Application No. 59/2013)
No. 42483). However, this invention
Because there is a conduit that passes blood cell components in the hollow fiber bundle of the plasma purification chamber (plasma fractionation membrane), the extracorporeal circulating blood volume increases,
In addition, the manufacturing process is time-consuming, and the plasma component fractionation hollow fiber membrane in the plasma purification chamber is not open on the joint side, making it difficult to clean during brimming and not being cleaned thoroughly, and air bubbles remain inside the hollow fiber. However, when blood is returned after extracorporeal circulation, purified plasma remaining in the hollow fibers is difficult to return.
一方、急速な血液浄化療法の発展に伴ない、血′ｔＬ製
剤、特に血漿製剤の不足が大きな社会問題となっている
。そのため、種々の血漿採取法が開発され、特に血液中
の血漿のみを採取する方法が普及しはじめてきている。On the other hand, with the rapid development of blood purification therapy, the shortage of blood products, especially plasma products, has become a major social problem. Therefore, various plasma collection methods have been developed, and in particular, methods for collecting only plasma from blood are becoming popular.
しかし、採取した血漿を各種の血漿製剤に分離するには
手間がかかり、また分離した後の血漿製剤もアルブミン
等の特定物質の盗要が多く、特定の血漿製剤が不足して
いるのが現状である。そのため、アルブミン等の特定の
分子量領域の物質のみを、簡単に採取できる方法の開発
が必要とされている。However, it is time-consuming to separate collected plasma into various plasma products, and specific substances such as albumin are often stolen from the separated plasma products, resulting in a shortage of specific plasma products. It is. Therefore, there is a need to develop a method that can easily collect only substances in a specific molecular weight range, such as albumin.
（発明の目的）
本発明は、上述の問題点を解決しようとするもので、二
重濾過血漿交換療法、選択的血漿成分採取法等の体液処
理を大巾に簡略化できる体液処理装置を提供するもので
ある。(Objective of the Invention) The present invention aims to solve the above-mentioned problems, and provides a body fluid processing device that can greatly simplify body fluid processing such as double filtration plasma exchange therapy and selective plasma component collection method. It is something to do.
（発明の構成）
本発明の体液処理装置は、それぞれ、膜孔径の異なる中
空系を内蔵した第１分離装置及び第２分離装置を、内部
通路を有する継手部を介して結合したことを特徴とする
。(Structure of the Invention) The body fluid treatment device of the present invention is characterized in that a first separation device and a second separation device each incorporating a hollow system having a different membrane pore diameter are connected via a joint portion having an internal passage. do.
以下、本発明装置を図面により説明する。第１図に示す
ように、継手部（３）を中心にして、一方の接続側に第
１分離装置（１）が、他方の接続側に第２分離装置（２
）が接続されている。第１分離装置及び第２分離装置に
は、そわぞれ多数本の中空糸が内蔵されているが、第１
分離装置内の中空糸と第２分離装置内の中空糸とは、膜
孔径を明確に異にしている。継手部は第１分離装置及び
第２分離装置と一体化されていてもよいし、必要に応じ
て着脱可能に結合されていてもよい。第１分離装置（１
）には、体液中の採取又は除去を目的とする物質（以下
「目的物質」と言う）が通過し、採取又は除去をしない
物質のうち目的物質よりも分子量の大きい物質が通過し
ない膜を用いる。例えば、第１分離装置に血漿分離器を
用いた場合には、血液中の血球成分を通過させず、血漿
成分あるいはアルブミンを主とする蛋白質を透す様な性
能を有する中空糸膜として、膜孔径１００〜４００ｎｍ
、膜面積０．０５〜１．０ｒｎ”の中空糸膜を使用する
。第１分離装置では、目的物質に応じて各種の膜が、例
えば、孔径１０〜５００ｎｍ、膜面積０．０５〜２．０
ｔｒｘ’の膜孔径グレードの膜が用いられる。一方、第
２分離装置（２）には、目的物質は通過させず、採取又
は除去をしない物質のうち目的物質よりも分子量の小さ
い物質が通過する膜を用いる。一般には、膜孔径４ｎｍ
〜５００ｎｍ、膜面積０．０５〜３゜０ｍ″の膜を使用
する。第１分離装置にょフて濾過された目的物質を含む
濾液は、目的物質と目的物質より分子量の小さい物質を
含んでいる。この濾液は、さらに第２分離装置によって
目的物質と、目的物質よりも分子量の小さい非目的物質
とにふるい分けられる。第２分離装置によって濾過され
た目的物質より分子量の小さい非目的物質は、第１分離
装置で濾過されなかった分子量の大きい物質と継手部内
の通路（６）で混合され、継手部の出口（１２）より取
り出される。例えば、第１分離装置（１）に血漿分離器
（膜孔径１００〜５００ｎｍ、膜面積０．０５〜２．０
ｒｎ２）、第２分離装置（２）に血漿成分分離器（血漿
分画膜、膜孔径１０〜ｌ１００ｎ、膜面８ＩＯ，１〜３
、 Ｏｒｎ”）を接続し、血液浄化を行なうと、血液は
第１分離装置により血球成分と血漿成分にふるい分けら
れ、濾過された血漿成分は第２分離装置によって有害な
免疫複合体などの高分子物質を多く含む血漿と、有益な
アルブミンなどの低分子物質を多く含む血漿とに濾過分
離され、濾過されなかった高分子物質を多く含む血漿は
廃棄し、濾過された低分子物質を多く含む血漿は、第１
分離装置によって濾過されなかった血球成分と継手部内
で混合され、浄化血液となワて継手部出口（１２）より
取り出される。第１図にはこの場合の血液の流れを矢印
で示している。体液中から採取又は除去する目的物質に
応じた膜孔径の膜を、各分離装置に使用することにより
、簡単かつ効率の良い採取又は除去を本装置によって実
施できる。The apparatus of the present invention will be explained below with reference to the drawings. As shown in Fig. 1, with the joint part (3) at the center, a first separating device (1) is located on one connecting side, and a second separating device (2) is located on the other connecting side.
) are connected. The first separation device and the second separation device each have a large number of hollow fibers built in.
The hollow fibers in the separation device and the hollow fibers in the second separation device have clearly different membrane pore diameters. The joint portion may be integrated with the first separation device and the second separation device, or may be detachably connected as necessary. First separation device (1
), use a membrane that allows the substance to be collected or removed from body fluids (hereinafter referred to as the "target substance") to pass through, but that does not allow the passage of substances that are not to be collected or removed but have a larger molecular weight than the target substance. . For example, when a plasma separator is used as the first separation device, the membrane is a hollow fiber membrane that does not allow blood cell components to pass through, but allows plasma components or proteins, mainly albumin, to pass through. Pore diameter 100-400nm
, a hollow fiber membrane with a membrane area of 0.05 to 1.0 nm is used. In the first separation device, various membranes are used depending on the target substance, for example, with a pore size of 10 to 500 nm and a membrane area of 0.05 to 2.0 nm. 0
A membrane with a membrane pore size grade of trx' is used. On the other hand, the second separation device (2) uses a membrane that does not allow the target substance to pass through, but allows a substance that is not collected or removed and that has a smaller molecular weight than the target substance to pass through. Generally, the membrane pore diameter is 4 nm.
~500nm and a membrane area of 0.05~3゜0m'' is used.The filtrate containing the target substance filtered through the first separation device contains the target substance and a substance with a molecular weight smaller than the target substance. This filtrate is further sieved into a target substance and a non-target substance with a molecular weight smaller than the target substance by a second separation device.The non-target substance with a molecular weight smaller than the target substance filtered by the second separation device is The substances with high molecular weight that were not filtered by the first separation device (1) are mixed in the passage (6) in the joint and taken out from the outlet (12) of the joint.For example, if the first separation device (1) is equipped with a plasma separator (membrane Pore diameter 100-500 nm, membrane area 0.05-2.0
rn2), the second separation device (2) is equipped with a plasma component separator (plasma fractionation membrane, membrane pore size 10-1100n, membrane surface 8IO, 1-3
, Orn") is connected and blood purification is performed, the blood is sieved into blood cell components and plasma components by the first separation device, and the filtered plasma components are separated from harmful immune complexes and other macromolecules by the second separation device. Plasma containing many substances and plasma containing many useful low-molecular substances such as albumin are separated by filtration.The unfiltered plasma containing many high-molecular substances is discarded, and the filtered plasma containing many low-molecular substances is discarded. is the first
The blood cell components not filtered by the separation device are mixed in the joint, and the purified blood is taken out from the joint outlet (12). In FIG. 1, the flow of blood in this case is shown by arrows. By using a membrane with a membrane pore size that corresponds to the target substance to be collected or removed from body fluids in each separation device, simple and efficient collection or removal can be performed by this device.
第３図は、２本の体液分離装置を血液回路で接続した公
知の回路図であり、第２図は本発明装置を用いた場合の
回路図である。FIG. 3 is a known circuit diagram in which two body fluid separation devices are connected by a blood circuit, and FIG. 2 is a circuit diagram when the device of the present invention is used.
本発明の装置によれば、第２図に示すように第３図に比
較して接続回路が少ないので、接続の手間及び接続間違
いを起こす可能性が減少でき、また洗浄性の向上、及び
洗浄時間の減少、体外循環血液流量の減少などの点で有
効性が認められる。According to the device of the present invention, as shown in FIG. 2, there are fewer connection circuits than in FIG. It is effective in reducing time and extracorporeal circulation blood flow.
また、本装置は、特開昭６１−１２２８７１号の装置に
比べても以下に述べるような利点がある。Furthermore, the present device has the following advantages compared to the device disclosed in Japanese Patent Application Laid-Open No. 122871/1983.
即ち、本装置は、第２分離装置の中空糸束の中に先願装
置の様な導管を必要としないため、製造の手間を減らす
ことができる。また、導管部容量分の体外血液循環容量
を減らすことができる。また第２分離装置の中空糸は継
手部側も開口（１１）しているため洗浄性が良好であり
、また気泡の消滅が早く、かつ残りにくい等の利点があ
る。That is, the present device does not require a conduit in the hollow fiber bundle of the second separation device, unlike the device of the prior application, so that the manufacturing effort can be reduced. Further, the extracorporeal blood circulation capacity can be reduced by the volume of the conduit portion. Furthermore, since the hollow fibers of the second separator have an opening (11) on the joint side, cleaning performance is good, and there are advantages such as air bubbles disappear quickly and are hard to remain.
次に、本発明を実施例によって具体的に説明する。Next, the present invention will be specifically explained using examples.
（実施例１）
第１分離装置に血漿分ＭＷ （セルロース・ジ・アセテ
ート製、膜面Ｍｏ、５ｄ、膜孔径２００ｎｍ、中空糸内
径３３０μｍ、膜厚７５μｍ）を、第２分離装置に血漿
分画膜（セルロース・ジ・アセテート製、膜面ｉ１１．
７ｒｎ’、膜孔径２５ｎｍ、中空糸内径２００μｍ、膜
厚７０μｍ）を用いた本発明の複合型体液処理装置を組
込んだ証液浄化処理回路を構成した。(Example 1) Plasma fraction MW (made of cellulose diacetate, membrane surface Mo, 5d, membrane pore diameter 200 nm, hollow fiber inner diameter 330 μm, membrane thickness 75 μm) was placed in the first separation device, and plasma fraction was placed in the second separation device. Membrane (made of cellulose diacetate, membrane surface i11.
7rn', membrane pore diameter of 25 nm, hollow fiber inner diameter of 200 μm, and membrane thickness of 70 μm).
患者から導出された血液は、血液ポンプにより体液人口
（７）から１００ ｍ ｊ２ ／ ｍ ｉ ｎの流量で
第１分離装置（１）内に入り、血漿分離膜（４）の中空
糸（図では中空糸を簡略化し１本で表わしているが、通
常は数千〜１１本が充填されている。）の内側を通り中
空糸出口（８）から継手部（３）の通路（６）゛に出る
。その過程で血液中の血漿の一部分は中空糸膜（４）の
外側に３０ｍｆＬ／ ｍ ｉ ｎの速さで濾過され、血
漿ポンプにより濾液出口（９）から導出され、第２分離
装置（２）の濾液入口（１０）に送られる。入口（１０
）に送られた、３０ｍｌ１／ｍｉｎの流量の血漿は、血
漿分画膜（５）の中空糸外側から内側に濾過され、中空
糸出口（１１）から継手部の内部通路（６）に出る。内
部通路（６）内で出口（８）から出てくる血球成分の豊
富な血液と混合された浄化血液は出口（１２）から取り
出される。不要な血漿は出口（１４）から排出する。尚
、血漿分画膜としては通過させるべき目的物質に応じて
、その孔径を膜孔径１０〜５０ｎｍ、膜面積０．５〜２
．０ゴの範囲内で選択使用する。Blood drawn from the patient enters the first separation device (1) at a flow rate of 100 m j2 /min from the body fluid population (7) by a blood pump and passes through the hollow fibers (in the figure) of the plasma separation membrane (4). Although the hollow fiber is simplified and shown as one, it is usually filled with several thousand to 11 fibers.) From the hollow fiber outlet (8) to the passage (6) of the joint (3). Get out. In the process, a part of the plasma in the blood is filtered outside the hollow fiber membrane (4) at a rate of 30 mfL/min, is drawn out from the filtrate outlet (9) by the plasma pump, and is transferred to the second separation device (2). to the filtrate inlet (10). Entrance (10
) at a flow rate of 30 ml/min is filtered from the hollow fiber outside to the inside of the plasma fractionation membrane (5) and exits from the hollow fiber outlet (11) to the internal passageway (6) of the joint. The purified blood, mixed in the internal passage (6) with the cell-enriched blood emerging from the outlet (8), is removed from the outlet (12). Unwanted plasma is discharged through the outlet (14). The plasma fractionation membrane has a pore size of 10 to 50 nm and a membrane area of 0.5 to 2 nm, depending on the target substance to be passed through.
．． Select and use within the range of 0.
第１分離装置に血漿分離膜を用い、第２分離装置に血漿
分画膜を用いて、特開昭６１−１２２８７１号の装置と
本発明装置とを比較した１例を表１に示す。Table 1 shows an example of a comparison between the apparatus of JP-A-61-122871 and the apparatus of the present invention, using a plasma separation membrane in the first separation apparatus and a plasma separation membrane in the second separation apparatus.
表１
（実施例２）
第１分離装置に血漿分画膜（セルロース・ジ・アセテー
ト族、膜面積１，７ば、膜孔径１３ｎｍ、中空糸内径２
００μｍ、膜厚７０μｍ）を、第２分離装置に血液濃縮
膜（ポリ・アクリロ・ニトリル族、膜面積０．８ｒｎ’
、膜孔径８ｎｍ、中空糸内径２００μｍ、８５５５μｍ
）を用いた本発明の複合型体液処理装置を組込んだアル
ブミン採取回路を構成した。Table 1 (Example 2) A plasma fractionation membrane (cellulose diacetate family, membrane area 1.7 mm, membrane pore diameter 13 nm, hollow fiber inner diameter 2 mm) was used in the first separation device.
00 μm, membrane thickness 70 μm) and a hemoconcentration membrane (poly-acrylo-nitrile family, membrane area 0.8rn') in the second separation device.
, membrane pore diameter 8 nm, hollow fiber inner diameter 200 μm, 8555 μm
) An albumin collection circuit incorporating the composite body fluid treatment device of the present invention using the following was constructed.
血液提供者から導出された血液は、血液ポンプにより入
口（７）から第１分離装置（１）に５０ｍｆＬ／ｍｉｎ
の流量で入り、中空糸血漿分画Ｍ（４）によって、アル
ブミン、電解質、ブドウ糖、水分などの低分子量血液成
分が１２ｒｎｌＬ／ｍｉｎの流速で濾過されて中空糸外
側に出る。濾過されなかった残りの血液成分は、中空糸
出口（８）から継手部（３）の内部通路（６）に出る。The blood drawn from the blood donor is transferred from the inlet (7) to the first separation device (1) at a rate of 50 mfL/min by a blood pump.
low molecular weight blood components such as albumin, electrolytes, glucose, and water are filtered by the hollow fiber plasma fraction M(4) at a flow rate of 12rnlL/min and exit to the outside of the hollow fiber. The remaining unfiltered blood components exit from the hollow fiber outlet (8) into the internal passageway (6) of the joint (3).
中空糸膜（４）の外側に濾過された低分子量血液成分は
、出口（９）より導出され、血漿ポンプにより、第２分
離装置（２）の入口（１０）から中空糸血液濃縮膜（５
）の外側部分に流量１２ｍＪ２／ｍｉｎで送られ、今度
は中空糸（５）の外側から内側へ濾過される。この際、
水分、電解質、ブドウ糖などのアルブミンより小さい分
子量の物質が濾過されて、中空糸内部に入り、中空糸出
口（１１）から１０ｍｕ／ｍｉｎの流量で継手部（３）
の内部通路（６）に出て、（８）からきた低分子量血漿
成分の少ない流量３８ｍ１／ｍｉｎの血液と継手部内の
混合部（６）で混合され、出口（１２）より４８ｍＩＬ
／ｍｉｎの流量で導出され提供者に返される。第２分離
装置の中空糸（５）で濾過されずに中空糸外側に残るア
ルブミン濃縮液は、出口（１４）より２ｍ２／ｍｉｎの
流量で導出され医療用血液製剤の用途に用いられる。The low molecular weight blood components filtered to the outside of the hollow fiber membrane (4) are led out from the outlet (9), and are transferred from the inlet (10) of the second separation device (2) to the hollow fiber hemoconcentration membrane (5) by a plasma pump.
) at a flow rate of 12 mJ2/min, and is then filtered from the outside to the inside of the hollow fiber (5). On this occasion,
Substances with a molecular weight smaller than albumin, such as water, electrolytes, and glucose, are filtered and enter the hollow fiber, and are passed through the joint (3) from the hollow fiber outlet (11) at a flow rate of 10 mu/min.
The blood flows out into the internal passageway (6) and mixes with the blood with a low flow rate of 38ml/min containing low molecular weight plasma components from (8) in the mixing part (6) in the joint, and from the outlet (12) at 48mIL.
/min flow rate and returned to the provider. The albumin concentrate remaining outside the hollow fiber without being filtered by the hollow fiber (5) of the second separation device is led out from the outlet (14) at a flow rate of 2 m2/min and used for medical blood products.
（発明の効果）
本発明装置は、公知の装置に比して、取扱いが簡単で、
接続回路も短縮でき、特定の目的物質の除去のみでなく
、採取をも極めて容易に実施できる。(Effects of the invention) The device of the present invention is easier to handle than known devices, and
The connection circuit can also be shortened, and not only the removal of a specific target substance but also the collection can be carried out extremely easily.
第１図は本発明装置の模式図。第２図は本発明装置の使
用状態を示す回路図。第３図は２本の体液分離装置を回
路で接続した公知の回路図である。FIG. 1 is a schematic diagram of the apparatus of the present invention. FIG. 2 is a circuit diagram showing how the device of the present invention is used. FIG. 3 is a known circuit diagram in which two body fluid separation devices are connected by a circuit.
Claims (10)
分離装置及び第２分離装置を、内部通路を有する継手部
を介して結合したことを特徴とする複合型体液処理装置
。(1) Each of the first tubes has hollow fibers with different membrane pore diameters.
A composite body fluid treatment device characterized in that a separation device and a second separation device are connected via a joint portion having an internal passage.
中空糸膜孔径より大きい特許請求の範囲（１）記載の複
合型体液処理装置。(2) The composite body fluid treatment device according to claim (1), wherein the hollow fiber membrane pore diameter of the first separation device is larger than the hollow fiber membrane pore diameter of the second separation device.
分離装置の中空糸が血漿分画膜である特許請求の範囲（
１）記載の複合型体液処理装置。(3) The hollow fiber of the first separation device is a plasma separation membrane, and the
Claims in which the hollow fibers of the separation device are plasma fractionation membranes (
1) The composite body fluid treatment device described above.
血漿分画膜である特許請求の範囲（１）記載の複合型体
液処理装置。(4) The composite body fluid treatment device according to claim (1), wherein the hollow fibers of the first separation device and the second separation device are both plasma fractionation membranes.
分離装置が血液濃縮器または血漿濃縮器である特許請求
の範囲（１）記載の複合型体液処理装置。(5) The hollow fiber of the first separation device is a plasma fractionation membrane, and the
The composite body fluid treatment device according to claim (1), wherein the separation device is a hemoconcentrator or a plasma concentrator.
分離装置が血液濃縮器または血漿濃縮器である特許請求
の範囲（１）記載の複合型体液処理装置。(6) The hollow fiber of the first separation device is a plasma separation membrane, and the hollow fiber of the first separation device is a plasma separation membrane.
The composite body fluid treatment device according to claim (1), wherein the separation device is a hemoconcentrator or a plasma concentrator.
の範囲（１）〜（６）のいずれか１つに記載の複合型体
液処理装置。(7) The composite body fluid treatment device according to any one of claims (1) to (6), wherein the joint portion has one or more body fluid outlets.
路に直結する混合部を形成している特許請求の範囲（１
）〜（７）のいずれか１つに記載の複合型体液処理装置
。(8) Claim (1) in which the internal passage of the joint part forms a mixing part directly connected to the hollow fiber internal passage of each separation device.
The composite body fluid treatment device according to any one of ) to (7).
請求の範囲（１）〜（８）のいずれか１つに記載の複合
型体液処理装置。(9) The composite body fluid treatment device according to any one of claims (1) to (8), wherein the second separation device has a recycling outlet.
る特許請求の範囲（１）〜（９）のいずれか１つに記載
の複合型体液処理装置。(10) The composite body fluid treatment device according to any one of claims (1) to (9), wherein the second separation device has an outlet for disposal or collection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP29469086A JPS63147473A (en) | 1986-12-12 | 1986-12-12 | Composite type body fluids treatment apparatus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP29469086A JPS63147473A (en) | 1986-12-12 | 1986-12-12 | Composite type body fluids treatment apparatus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS63147473A true JPS63147473A (en) | 1988-06-20 |
Family
ID=17811044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP29469086A Pending JPS63147473A (en) | 1986-12-12 | 1986-12-12 | Composite type body fluids treatment apparatus |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS63147473A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005118506A (en) * | 2003-10-14 | 2005-05-12 | Shoichi Kin | On-line massive fluid replacement type hemodialyzer |
| JP2010069278A (en) * | 2008-09-22 | 2010-04-02 | 成一 ▲高▼杉 | Body fluid purifier which can be embedded in body |
-
1986
- 1986-12-12 JP JP29469086A patent/JPS63147473A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005118506A (en) * | 2003-10-14 | 2005-05-12 | Shoichi Kin | On-line massive fluid replacement type hemodialyzer |
| JP2010069278A (en) * | 2008-09-22 | 2010-04-02 | 成一 ▲高▼杉 | Body fluid purifier which can be embedded in body |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5858238A (en) | Salvage of autologous blood via selective membrane/sorption technologies | |
| EP1993631B1 (en) | Regeneratable filter for extracorporal treatment of liquids containing particles and use thereof | |
| EP0990444B1 (en) | Septicemia prevention and treatment system | |
| CN1761494B (en) | Blood treatment device by selective solute extraction | |
| JPH07507463A (en) | Apparatus and method for producing leukocyte-free platelet concentrate | |
| CN105209088B (en) | Equipment for removing protein-bound toxins from blood plasma | |
| GB1562546A (en) | Removing specific factors from blood | |
| JPH0261265B2 (en) | ||
| JP2001061955A (en) | Autotransfusion device and method | |
| WO2006012885A1 (en) | Filter system for treating liquids containing particles using membrane isolation and adsorption | |
| US5498340A (en) | Processing of protein-containing body fluids | |
| JPS63147473A (en) | Composite type body fluids treatment apparatus | |
| JPS5911865A (en) | Blood purifier | |
| JP2961481B2 (en) | Hemodialyzer and hemofilter | |
| JPS61501249A (en) | Priming system for ultrafiltration units | |
| CN106659834A (en) | System for removing pro-inflammatory mediators as well as granulocytes and monocytes from blood | |
| JPS6362B2 (en) | ||
| JPH01291871A (en) | Treatment of abdominal dropsy | |
| CN216022409U (en) | Neuroimmune disease treatment system | |
| Nosé et al. | Plasmapheresis and cytapheresis | |
| CN111529784B (en) | CPFA (coherent population FA) bridging pipeline | |
| DE10216744A1 (en) | Device for purifying blood, useful for the treatment or prevention of e.g. allergy or autoimmune disease, comprises labeling separated cellular and plasma fractions with specific markers, followed by recombination of the purified components | |
| JPH05115544A (en) | Blood corpuscle-blood plasma separating circuit and blood purifying device using the same | |
| CA1293928C (en) | Thermofiltration of plasma | |
| JPS62236553A (en) | Pretreatment of membrane type blood purifier |